Posters from the Academy of Managed Care Pharmacy (AMCP)’s annual meeting examined the real-world patterns of biosimilar utilization and the impact of products that have been reclassified as biologics on Medicaid spending.
Posters from the Academy of Managed Care Pharmacy (AMCP)’s annual meeting examined the real-world patterns of biosimilar utilization and the impact of products that have been reclassified as biologics on Medicaid spending.
Real-world Patters of Oncology Biosimilars1
Use of biosimilars was found to result in significant cost savings without requiring increased utilization other health care resources, suggesting that they are an ideal alternative to a reference, according to researchers at Intermountain Healthcare and SelectHealth.
Biosimilars offer patients and payers access to lower-cost alternatives to expensive reference products, and more research is needed to show the full financial and clinical impacts of increasing biosimilar utilization.
The researchers collected data on patient claims from SelectHealth, Medicaid, and commercial medial and pharmacy claims for bevacizumab, trastuzumab, and rituximab products between July 1, 2013 and September 21, 2021. In total, 1830 patients had claims for a reference product (Avastin, Herceptin, Rituxan, respectively) and 414 patients had claims for a biosimilar.
Two rituximab biosimilars (Truxima and Ruxience), 3 trastuzumab biosimilars (Ontruzant, Trazimera, and Kanjinti), and 2 bevacizumab biosimilars (Mvasi, Zirabev) were included in the analysis.
Biosimilars for the 3 molecules were found to be statistically significantly cheaper per claim, with cost per claim amounting to approximately $1056 less compared to claims for the reference products. The authors said that this could results in significant cost savings per year for patients and payers.
When claims were divided by the number of patients per product, there were no significant differences observed in supportive care claims between them, suggesting that further investigation into the supportive care space is needed.
Impact of Reclassified Biologic Products on Medicaid Spending2
Although the BPCIA’s follow-on pathways were effective at promoting follow-on competition among long-acting insulins, millions more in savings for Medicaid could have been provided if biologic reclassification was done in 2010 instead of 2020.
Furthermore, if reclassification occurred in 2010, development time, drug patents, and other barriers would likely have delayed competitive biosimilars from entering the market. However, the products may have been able to enter the market before 2021.
The BPCIA is the regulatory work that established the approval pathway for biologics and biosimilars. In 2020, some products, such as insulins, growth hormones, digestive enzymes, that were approved by the FDA using new drug applications were reclassified as biologics as a way to increase competition.
To understand the current level of market competition, the researchers collected data from the Medicaid State Drug Utilization Data between 1991 and 2021 for all reclassified drugs. Afterwards, they estimated the cost of the 10-year preparation period for long-acting insulin products, essentially providing another 10 years of exclusivity for the reference product (Lantus).
The estimated difference in gross reimbursement from 2010 and 2020 was found to be about $4.5 million in missed savings for Medicaid.
The investigators said that the ultimate impact of the BPCIA is still unknown and the introduction of Semglee (insulin glargine), the first biosimilar to receive interchangeability status in the United States, showed promise for additional insulin competition and future interchangeable biologic products.
Semglee entered the market in late 2020 and was automatically priced lower than Lantus and Basaglar. The authors theorized that net costs for insulin glargine could be further reduces as more competitive products like Semglee enter the market.
“Continuing this analysis in 5-10 years will reveal the actual impact of any additional competitors on the reimbursement levels for insulins, growth hormones, enzymes, and other biologic classes,” the investigators said.
Reference
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.